July 08, 2024
Community Shares | July 8th 2024
A new review has investigated the potential use of immunomodulating agents to treat neuroinflammation in patients with autism, who often do not respond to standard treatments. Neuroinflammation, influenced by genetic, epigenetic, and environmental factors, is considered a significant contributor to ASD. This work highlights that some existing anti-inflammatory treatments have shown promise, including corticosteroids, intravenous […]
April 24, 2023
CDC Reports: 26.7 % of People with ASD Meet the Criteria for “Profound Autism”
The Centers for Disease Control and Prevention (CDC) recently reported that 26.7% of individuals with autism qualify as having “profound autism,” defined as having the disorder with an intelligence quotient (IQ) score <50 or being nonverbal or minimally verbal.
